伊立替康联合顺铂一线治疗晚期非小细胞肺癌

目的:观察伊立替康(商品名开普拓)每周给药联合顺铂治疗晚期非小细胞肺癌(NSCLC)的疗效以及不良反应。方法:经病理学或细胞学确诊的初治晚期NSCLC患者13例,男性8例,女性5例,中位年龄48岁,KPS评分>70。接受顺铂60~80mg/m2联合开普拓60mg/m2第1、8、15天静脉滴注,每4周重复。至少2周期以上可评价疗效及不良反应。结果:全组PR3例,SD9例,PD1例,总有效率为23%。中位生存时间12.5个月,1年生存为率70%(7/10)。主要不良反应为延迟性腹泻和粒细胞减少。结论:开普拓每周给药联合顺铂治疗晚期NSCLC疗效确切,不良反应发生率低,耐受性较好。

Irinotecan in combination with cisplatin for advanced NSCLC

Purpose:To evaluate the efficacy and side effects of weekly administration of irinotecan (CPT-11) combined with cisplatin (PDD) in the treatment of advanced NSCLC. Methods:Thirteen previously untreated patients were enrolled, who were diagnosed as advanced NSCLC by pathology or cytology, including 8 men and 5 women.The median age was 48 years(range, 33 to 56 years) KPS>70. CPT-11 was given at 60-80 mg/m~ 2 by intravenous infusion on days 1,8,15, and PDD given as 60-80 mg/m~ 2 by intravenous infusion. This regimen was given every 4 weeks. Results:The objective response rate was 23%, and included 3 partial responses ,9 stable disease,1 progressive disease and none complete response. The median survival time and the actual 1-year survival rate were 10.5 months and 53.8% (7/13) respectively. The major clinical toxicities were late-onset diarrhea and neutropenia. Conclusions:The combination of CPT11 and PDD is effective and well tolerated in the treatment of advanced NSCLC, and side effects were mild.